Multidrug resistance after lamivudine therapy for chronic hepatitis B

摘要

Besides interferon, five oral nucleos(t)ide analogues are currently approved for the treatment of chronic hepatitis B (CHB): lamivudine (LAM), adefovir dipivoxil (ADV), entecavir (ETV), tenofovir (TDF) and telbivudine (LdT). Treatment of CHB with any single nucleoside reverse transcriptase inhibitor (NRTI) generally leads to rapid suppression of viral replication in the short term; however, long-term therapy can cause the emergence of drug-resistant mutants.1,2 Lamivudine, the first NRTI approved for CHB therapy, is still commonly used as the first-choice therapy for its potency, relatively low cost and safety profile.